Skip to content
TrialScanner

NCT05933070

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

Phase 1TerminatedINMBLead

Registry record

Lead sponsor
Inmune Bio, Inc.
Conditions
Cancer; MDS-EB; Myelodysplastic Syndromes; Acute Myeloid Leukemia; AML
Primary completion
Mar 28, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05933070 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05933070: A Phase I Open-Label Dose... | TrialScanner